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Abstract 
Adenoma miss rates in colonoscopy are unacceptably high, especially for sessile serrated adenomas 
/ polyps (SSA/Ps) and in high-risk populations, such as patients with Lynch syndrome. Detection 
rates may be improved by fluorescence molecular endoscopy (FME), which allows morphological 
visualization of lesions with high-definition white-light imaging as well as fluorescence-guided 
identification of lesions with a specific molecular marker. In a clinical proof-of-principal study, we 
investigated FME for colorectal adenoma detection, using a fluorescently labelled antibody 
(bevacizumab-800CW) against vascular endothelial growth factor A (VEGFA), which is highly 
upregulated in colorectal adenomas.  
Methods: Patients with familial adenomatous polyposis (n = 17), received an intravenous injection 
with 4.5, 10 or 25 mg of bevacizumab-800CW. Three days later, they received NIR-FME.  
Results: VEGFA-targeted NIR-FME detected colorectal adenomas at all doses. Best results were 
achieved in the highest (25 mg) cohort, which even detected small adenomas (<3 mm). 
Spectroscopy analyses of freshly excised specimen demonstrated the highest adenoma-to-normal 
ratio of 1.84 for the 25 mg cohort, with a calculated median tracer concentration in adenomas of 
6.43 nmol/mL. Ex vivo signal analyses demonstrated NIR fluorescence within the dysplastic areas of 
the adenomas.  
Conclusion: These results suggest that NIR-FME is clinically feasible as a real-time, red-flag 
technique for detection of colorectal adenomas. 











Colorectal cancer (CRC) is the second most 
common cancer worldwide, accounting for 8% of all 
cancer related deaths [1]. Of all CRCs, approximately 
60% develops via the well-known adenoma- 
carcinoma sequence, one-third via the alternative 
serrated pathway and a small portion from Lynch 
syndrome (LS) [2]. White-light endoscopy is 
considered the gold standard for detection and 
removal of colorectal lesions, to prevent CRC 
development. However, detection of small adenomas 
(<5 mm) and sessile serrated adenomas / polyps 
(SSA/P) is difficult since conventional endoscopy 
relies upon aspecific morphological tissue signatures 
and thus on the experience of the endoscopist. As a 
result, the reported adenoma detection miss rate for 
the general population is relatively high (27%) [3]. For 
patients with LS, adenoma miss rates are even up to 
55%. In this high-risk population small adenomas are 
more common, and these often already contain 
high-grade dysplasia (HGD) since the adenoma- 
carcinoma sequence is known to be accelerated [4,5]. 
Therefore, missed lesions can rapidly progress to 
cancer which results in an unacceptable cumulative 
cancer risk of up to 35% at the age of 60, despite 
intensive screening programs. This underscores the 
necessity of improving endoscopic detection 
strategies [6].  
One way to improve endoscopic lesion 
identification is the incorporation of wide-field 
fluorescence molecular endoscopy (FME). FME 
visualizes lesions based on their biological properties 
rather than their morphology; it uses exogenous 
fluorescent tracers that bind to specific proteins, 
thereby fluorescently ‘highlighting’ the tissue of 
interest as a ‘red-flag’ for the endoscopist. A recently 
published study showed a higher adenoma detection 
rate with FME following an intravenous (IV) injected 
anti-cMET tracer using an old white-light fiber 
endoscope for both fluorescence and white-light 
imaging, which hampers clinical translation [7]. 
Moreover, FME in the visible spectrum limits the 
sensitivity and contrast available to the fluorescence 
method. Separation of weak fluorescence signals in 
the presence of strong white-light illumination 
requires several orders of magnitude spectral 
separation through filters, which also reduces 
significantly the transmission of fluorescence signals. 
Moreover, the visible light exhibits strong 
autofluorescence, reducing contrast.  
Therefore, we labelled the monoclonal antibody 
bevacizumab with a near-infrared (NIR) fluorescent 
dye, IRDye 800CW, and used a NIR-FME platform 
that enables concurrent fluorescence and 
high-definition (HD) white-light imaging. 
Bevacizumab-800CW binds vascular endothelial 
growth factor A (VEGFA), which is present in all 
stages of colorectal neoplasms, including low grade 
dysplastic (LGD) adenomas and in up to 90% of 
difficult to detect but clinically important sessile 
serrated adenomas/polyps (SSAPs) [8,9]. We 
evaluated VEGFA-targeted NIR-FME for adenoma 
detection in a dose-escalation study, performed in 
patients with familial adenomatous polyposis (FAP) 
who have a high probability of occurrence of 
colorectal adenomas. We choose FAP patients due to 
the abundance of colorectal adenomas in this 
condition, to enable adequate evaluation of the 
different dose steps. To validate our in vivo NIR-FME 
findings, we quantified the fluorescence of excised 
colorectal tissue by correcting for the influence of 
tissue optical properties using Multi-Diameter Single 
Fiber Reflectance and Single Fiber Fluorescence 
(MDSFR/SFF) spectroscopy (Figure 1).  
Materials and Methods  
Study population and design  
Patients with FAP that were 18 years of age or 
older, and scheduled for surveillance endoscopy at 
the University Medical Center Groningen (UMCG), 
were invited to participate in the study. Trial 
enrolment required FAP to be genetically proven or 
clinically diagnosed by >100 colorectal adenomatous 
polyps at earlier endoscopy. Patients with a MutY 
human homolog gene (MUTHY) mutation or who had 
a proctocolectomy were excluded. The study protocol 
was approved by the Medical Ethics Committee of the 
UMCG. All patients gave their written informed 
consent for participation in the study before inclusion. 
The study was registered with ClinicalTrials.gov 
(NCT02113202). 
 This non-randomized, non-blinded, single 
center proof-of-principle study consisted of three 
tracer-dose cohorts: 4.5, 10 and 25 mg of 
bevacizumab-800CW (Figure 1A) [10]. These tracer 
dosages are low compared to the therapeutic dose of 
bevacizumab (5-10 mg/kg) [11]. Three days after IV 
tracer injection, patients underwent surveillance 
endoscopy with a HD endoscope followed by 
NIR-FME to visualize fluorescent signals. Afterwards, 
we validated the observed fluorescence by ex vivo 
signal quantification on fresh resected tissue with 
MDSFR/SFF spectroscopy. Additionally, to specify 
tracer distribution and enable correlation to 
histopathology, we performed NIR-fluorescence 
flatbed scanning, fluorescence microscopy and 
VEGFA immunohistochemistry (IHC) on formalin- 
fixed, paraffin-embedded (FFPE) tissue (Figure 1B).  





In the 4.5 mg cohort, six FAP patients with 
adenomas were included. The interim analysis 
incorporated in our study protocol allowed for a 
tracer dose escalation if the 4.5 mg tracer dose 
appeared suboptimal. As a result, three patients were 
included in the subsequent dose cohorts (10 and 25 
mg); the best-performing tracer-dose cohort (25 mg) 
was expanded to six FAP patients in total. All 
observed adverse events were noted until 72 h after 
intravenous tracer injection. This period was chosen 
as bevacizumab-800CW had shown a good safety 
profile in previous studies in patients with primary 
breast cancer and peritoneal carcinomatosis of 
colorectal origin [12]. 
NIR-FME procedure  
Endoscopy was performed after standard bowel 
preparation, optionally under conscious sedation with 
midazolam and fentanyl. All procedures were 
performed with a routine clinical HD video 
endoscope, which is standard of care during 
surveillance endoscopies (CF-H180AL/I or GIF- 
H180J; EVIS EXERA II; Olympus Corporation, Tokyo, 
Japan). White light was provided by a standard xenon 
light source (CLV-180 Evis Exera II; Olympus 
Corporation), in which a short pass filter was installed 
(<750 nm, E700SP-2P; Chroma, Bellows Falls, VT, 
USA). When the caecum or ileorectal anastomosis was 
reached, the NIR-FME probe was introduced in the 
working channel of the video endoscope (online 
Figure S1A) [13]. During withdrawal, adenomas were 
concurrently visualized with both the video 
endoscope and the NIR-FME probe. The NIR-FME 
images (color, fluorescence and overlay) were 
displayed on a separate monitor (Figure 2). 
Subsequently, all large adenomas (≥5 mm; standard 
clinical care) and a maximum of six small adenomas 
(<3 mm) were excised. Additionally, four biopsies of 
normal appearing colorectal mucosa were taken for 
research purposes only. See supplementary materials 
for detailed information on tracer production and the 
technical background of the NIR-FME system. 
MDSFR/SFF spectroscopy 
The freshly resected adenomas and normal 
mucosa biopsies were placed on ice with the mucosal 
side upwards. Directly after the endoscopy the 
MDSFR/SFF spectroscopy probe was placed on top of 
the fresh tissue for quantitative measurements of NIR 
fluorescence. This device gains two reflectance spectra 
via two different optical fibers and subsequently one 
raw fluorescence spectrum (Figure S1B and S2). From 
the reflectance spectra, the scattering and absorption 
coefficients were determined, which were used to 
determine the intrinsic fluorescence. The intrinsic 
fluorescence was afterwards used to calculate the 
actual bevacizumab-800CW concentration present in 
the fresh resected tissue. Subsequently, the majority of 
resected adenomas and normal tissue biopsies were 
formalin-fixed and paraffin-embedded (FFPE), while 
some were snap-frozen in liquid nitrogen and stored 
at -80°C. In one patient (25 mg cohort) no quantitative 
measurements could be collected due to a technical 
malfunction of the MDSFR/SFF spectroscopy device. 
See supplementary materials for more detailed 
information on the MDSFR/SFF spectroscopy device, 




Figure 1. Study design. (A) Intravenous administration of the fluorescent tracer bevacizumab-800CW, three days later followed by VEGFA-targeted fluorescence endoscopy. 
(B) Ex vivo fluorescent signal analyses: 1) quantification of the fluorescence signals with MDSFR/SFF spectroscopy, performed on fresh resected tissue, and 2) qualitative evaluation 
of tracer distribution performed on FFPE tissue. CR, colorectal; FFPE, formalin-fixed and paraffin-embedded; H&E, hematoxylin and eosin; IHC, immunohistochemistry; 
MDSFR/SFF, multi-diameter single fiber reflectance and single fiber fluorescence; NIR-FME, near-infrared fluorescence molecular endoscopy; VEGFA, vascular endothelial growth 
factor A.  





Histological fluorescence mapping  
Per FFPE tissue block, one 10 µm section and 
three 4 µm sections were sliced, mounted on 
silane-coated slides and dried overnight at 37 °C. The 
10 µm FFPE tissue sections were deparaffinized (10 
min xylene) and imaged with the NIR fluorescence 
flatbed. Afterwards, the 10 µm tissue sections and the 
subsequent 4 µm tissue sections were stained with 
hematoxylin and eosin (H&E). The H&E slides were 
digitalized by the Nanozoomer 2.0-HT slide scanner 
(Hamamatsu) and viewed with use of NanoZoomer 
Digital Pathology (NDP) viewer software 
(Hamamatsu). Blinded for the fluorescence signals 
and under supervision of an experienced 
gastrointestinal pathologist (A.K.), different tissue 
areas were selected: low-grade dysplasia (LGD) areas 
within the adenoma, normal adjacent tissue within 
the adenoma section and normal colon crypts within 
the normal tissue biopsies. Afterwards, these areas 
were superimposed on the NIR fluorescence Odyssey 
images. Ex vivo analyses of the snap frozen tissue was 
shown to be unreliable, as bevacizumab-800CW 
signals diminished during thawing of the samples. 
Fluorescence microscopy  
 For fluorescence microscopy, 4 µm FFPE tissue 
sections were deparaffinized, rehydrated and stained 
with Hoechst to visualize nuclei (33258; Invitrogen, 
Thermo Fisher Scientific). Fluorescence microscopy 
was performed using an inverted wide-field 
microscope (63-100x magnification, immersion oil; 
DMI6000B, Leica Biosystems GmbH, Nussloch, 
Germany), with a LED light source that is able to 
excite up to 900 nm (X-Cite 200DC; Excelitas 
Technologies, Waltham, MA, USA), a monochrome 
camera also sensitive in the NIR range (1.4M Pixel 
CCD, DFC365FX; Leica Biosystems GmbH) and an 
adapted filter set (two band-pass filters 850-90m-2p 
and a long-pass emission filter HQ800795LP; Chroma 
Technology). All tissue slides were assessed using the 
same settings to enable visual comparison. Following 
acquisition, the images were processed with LAS-AF2 
software (Leica Microsystems).  
Immunohistochemical analysis of VEGFA 
expression  
We previously demonstrated the relevance of 
VEGFA as a target for colorectal neoplasia [8]. To 
determine if the prior VEGFA results hold true for our 
current patient population, we immunostained all 
FFPE colorectal tissue collected during this study 
(polyclonal rabbit anti-human VEGFA, RB9031 1:300; 
Thermo Fisher Scientific, Waltham, Ma, USA). To 
ascertain specific binding of the anti-VEGFA 
antibody, a positive tissue control and a negative IgG 
control were included. Dysplastic crypts, normal 
crypts within the adenoma section and normal 
mucosa derived from the biopsies were scored 
separately for their staining intensity (0-3 scale) and 
the percentage of cells stained. This visual scoring was 
performed by two separate observers (E.H. and 
J.J.J.T.). Subsequently, H-scores were generated 
(continuous scale: 0-300) by combining the evaluated 
intensity and the corresponding percentage of cells 
stained [14]. See supplementary materials for detailed 
description of the IHC methods and H-score formula. 
Statistics  
For statistical analysis of the MDSFR/SFF 
spectroscopy and flatbed scanning results IBM SPSS 
22.0 (IBM Corporation, Armonk, NY, USA) and 
GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, 
CA, USA) were used. A two-tailed t test, 
Mann-Whitney U test or Kruskal-Wallis test was 
used, according to sample-size and distribution. P 
values <0.05 were considered statistically significant.  
Results 
Near-infrared fluorescence molecular 
endoscopy (NIR-FME)  
In total, 17 patients participated in the study 
(Table 1). Eight patients received 4.5 mg, three 
patients 10 mg and another six patients 25 mg 
bevacizumab-800CW intravenously. No tracer-related 
adverse events were observed (0/17). Two patients in 
the 4.5 mg cohort did not have any lesions at 
endoscopy and were excluded from further analyses. 
Table 1. Patient and adenoma characteristics 
Number of patients, n (%) 17  
Complete colon in situ 5 (29.4%) 
Ileorectal anastomosis 12 (70.6%) 
Sex, n (%)   
 Male 5 (29.4%) 
 Female  12 (70.6%) 
Age, in years   
 Median (range) 42 (20-65) 
Total number of observed adenomas per patient, n 
(%) 
  
 0 2A (11.8%) 
 1-5 4 (23.5%) 
 6-20 10 (58.8%) 
 >20 1 (5.9%) 
Histology of resected lesions, n (%) 51 (100%) 
 LGD adenomatous polyp 50 (98%) 
 HGD adenomatous polyp 1 (2%) 
A The two patients without any adenomas at endoscopy were left out of the ex vivo 
fluorescent signal analyses. 
 
 For all three tracer-dose cohorts, VEGFA- 
targeted NIR-FME fluorescently visualized all 
adenomas identified with white-light HD inspection 
concurrently (sensitivity 100%) (Figure 2). All larger 
adenomas (≥5 mm) showed sufficient fluorescent 





contrast for direct in vivo detection at video rate (10 
frames per second [FPS]). Small adenomas (<3 mm) 
were clearly fluorescent in the 25 mg 
bevacizumab-800CW dose cohort enabling real-time 
visualization of all adenomas at video rate (Figure 3 
and Video S1 and S2), though the fluorescence signal 
varied in the 4.5 mg bevacizumab-800CW dose cohort 
hampering real-time detection in this lowest dosing 
cohort. Moreover, we were even able to detect small 
adenomas (<3 mm) present in the background of 
bright fluorescent adenomas (Figure 3 – second row). 
Normal colorectal mucosa showed only minimal 
fluorescence, resulting in a clear delineation of the 
fluorescent adenomas. We did not observe false 
positives in this feasibility study since 
normal-appearing colorectal tissue during HD 
inspection showed no significant NIR fluorescence 
with NIR-FME. In a few cases, where bowel 
preparation was insufficient, we did observe a 
detectable amount of NIR fluorescence in remaining 
feces. This NIR fluorescence is probably due to the 
native fluorescence present in fecal remnants, most 
likely originating from unrefined chlorophyll- 
containing ingredients like spinach [15].  
MDSFR/SFF spectroscopy: fluorescent signal 
quantification  
In total, the intrinsic fluorescence intensities 
were determined of 39 adenomas and 27 normal colon 
biopsies. This revealed a median adenoma-to-normal 
ratio for the 25 mg dose cohort of 1.84. There was a 
40% increase of intrinsic fluorescence of adenomas for 
the 25 mg cohort compared to the 10 mg cohort 
(Figure 4). In contrast, the intrinsic fluorescence 
intensities of normal tissue remained constant for all 
dose cohorts. The correction factor to correct the raw 
fluorescence for tissue optical properties ranged 
between 1.65 and 3.57. Tissue absorption, mainly by 
hemoglobin, was the main actor in this, while 
differences in scattering made a smaller but still 
significant contribution. The resulting intrinsic 
fluorescence spectra resembled the emission spectrum 
of bevacizumab-800CW in PBS, which confirms that 
the measured fluorescent signals are tracer derived 
(Figure S2). 
Based on the intrinsic fluorescence determined 
with MDSFR/SFF spectroscopy, an estimation could 
be made of the tracer concentration present in the 
tissue. This showed a median bevacizumab-800CW 
concentration 4.81 nmol/mL in the 10 mg adenomas, 
compared to 6.86 nmol/mL in the 25 mg adenomas. 
The median tracer concentration in normal tissue was 
3.82 nmol/mL (10 mg cohort) vs 3.73 nmol/mL (25 
mg cohort). These quantified measurements confirm 
our in vivo NIR-FME results, in which we observed 
improved fluorescence visualization of adenomas in 
the 25 mg dose cohort. 
 
Figure 2. Wide-field VEGFA-targeted fluorescence endoscopy. Three 
adenomas per tracer-dose cohort. The clinical white-light images gained with a HD 
video endoscope (first column), combined with representative overlay images (second 
column) and NIR fluorescence images (third column) gained with the NIR fiber bundle. 
The overlay images are automatically generated by the software, showing the highest 
fluorescence intensities in bright green and the very low fluorescence intensities as 
absent. The fluorescence images were taken with different exposure times. 






Figure 3. Real-time in vivo NIR-FME images. Adenomas from the 25 mg dose 
cohort demonstrating the ability of the NIR-FME system to visualize small and flat 
adenomas at video frame rate (10 frames per second). The white arrow indicates a 
second small adenoma. The overlay images are automatically generated by the 
software, showing the highest fluorescence intensities in bright green and the very 
low fluorescence intensities as absent.  
 
Figure 4. Fluorescence quantification by MDSFR/SFF spectroscopy. Box 
plot (median, 10-90 percentile) showing the intrinsic fluorescence (Q.µfa,x) per 
bevacizumab-800CW tracer-dose cohort for both LGD containing adenomas and the 
normal colorectal tissue (biopsies). For all dose cohorts, a significant difference in 
fluorescence intensity can be observed between the benign and premalignant tissue, 
which increases with increasing tracer dosages. Note that the fluorescence in the 
normal tissue stays constant in the 10 and 25 mg cohorts, regardless of the tracer 
dose used. The median adenoma-to-normal ratio of intrinsic fluorescence was 1.84 
for the 25 mg cohort. * = P < 0.05; ** = P < 0.001.  
 
Ex vivo tissue analyses: fluorescent signal 
qualification.  
In total, 49 FFPE adenomas (4.5 mg n = 21; 10 mg 
n = 11; 25 mg n = 17) and 24 normal tissue biopsies (4.5 
mg n = 8; 10 mg n = 4; 25 mg n = 12) were analyzed. Of 
the 49 FFPE adenomas, 48 contained LGD and one 
showed HGD. Within the adenomas, the tracer was 
mainly localized in the dysplastic areas compared to 
the normal tissue within the adenoma section (Figure 
5A). NIR fluorescence was localized between the 
adenomatous crypts, within the stromal tissue (Figure 
5B). Normal colorectal tissue within the sections of 
adenomas and in the normal mucosa biopsies both 
showed negligible NIR fluorescence (Figure 5C).  
Target-validation: VEGFA 
immunohistochemistry 
We observed a clear difference in VEGFA 
expression levels between the dysplastic crypts and 
the normal colon crypts (Figure 6). All adenoma 
samples expressed VEGFA, of which 96% showed a 
high staining intensity and 4% an intermediate 
staining (mean H-score: 286). In contrast, the normal 
colon tissue showed a lower mean intermediate 
H-score, namely 123 for normal crypts within the 
adenoma sections, versus 174 for biopsies of normal 
mucosa.  
Discussion 
In this study, we demonstrate that colorectal 
adenomas can be identified with VEGFA-targeted 
NIR-FME with concurrent high-definition white-light 
endoscopy. Based on the real-time observations in 
FAP patients, we identified 25 mg bevacizumab- 
800CW as the best-performing tracer dose. With this 
dose, we were able to identify all small (<5 mm) 
adenomas at video-rate, even if those were situated in 
the background of the image, behind a larger 
fluorescent adenoma. Detailed ex vivo fluorescent 
signal analyses with MDSFR/SFF spectroscopy and 
microscopy confirmed the specificity of the obtained 
results. As such, we believe that VEGFA-targeted 
NIR-FME has the potential to improve real-time, 
wide-field colorectal adenoma identification. With 
this first feasibility and dose-finding study, the way is 
cleared to start a study in high risk patients, to 
objectify its ‘red-flag’ ability in identifying and 
improving detection of flat and depressed adenomas. 
Previously described targeted FME approaches 
have been mainly restricted to preclinical application; 
they described the potential of a wide range of 
molecular targets, fluorescent labels and 
administration routes, as well as the use of both 
wide-field macroscopic and microscopic imaging 
systems [16,17]. Clinically, different approaches have 
been tried to obtain wide-field FME for colorectal 
adenoma detection. Mayinger showed in a feasibility 
study improved detection of small adenomas after 





topical application of Hexaminolevulinate (HAL). 
Since HAL absorption time is around 60 min, tracer 
administration is challenging. In this study the tracer 
was administered via an enema which might hamper 
detection of right-sided lesions [18]. A fluorescent 
tracer targeting cMET showed promising positive 
results, though fluorescence imaging was compared 
with outdated fiber white-light detection which does 
therefore not reflect current clinical practice [7]. Joshi 
et al. nicely demonstrated specific binding, using ex 
vivo quantification and correction, of a small 
fluorescent peptide after topical administration on 
SSA/Ps in the proximal colon identified with 
white-light HD endoscopy [19]. Future studies 
applying the tracer before HD identification of the 
lesions should elucidate the real-time identification 
potential of promising tracers as “red-flag” technique. 
Our FME approach is distinctive from former 
approaches since we used a tracer in the NIR range to 
optimally provide instant red-flag identification of 
colorectal lesions. The fluorescence and white-light 
images could concurrently be captured, as 
bevacizumab-800CW emits fluorescent light outside 
of the visible light spectrum; in the NIR light 
spectrum. Hence, the fluorescent signals could 
instantly be superimposed on the white-light images 
shown to the endoscopist. The clear discrimination 
between colorectal adenomas and normal tissue is a 
result of the accumulation of the IV injected 
bevacizumab-800CW specifically in colorectal 
adenomas, and the negligible attribution of human 
autofluorescence in the NIR light spectrum. Future 
software improvements could automatically alert the 
endoscopist and thereby even reduce the human 
factor which might improve adenoma detection rates. 
 Most likely the optimal tracer dose used during 
NIR-FME will have to be determined per tracer, organ 
of interest and indication. The aim of this study was to 
identify the best dose of IV bevacizumab-800CW for 
colorectal adenoma identification purposes. In cancer 
lesions it is thought that, due to the enhanced 
permeability and retention (EPR) effect, antibodies 
will accumulate easily, even when only a microdose 
of tracer is used [20]. However, in case of 
precancerous lesions, such as adenomatous polyps in 
which vascular hyperpermeability is not yet present, a 
higher tracer dose may be required to ensure 
sufficient fluorescent signal strength.  
 
Figure 5. Ex vivo fluorescent signal analyses. (A) Representative NIR fluorescence flatbed scan of a fluorescent adenoma (10 mg dose cohort), containing both dysplasia and 
normal colon crypts in the same section (HE staining). The fluorescence scan and interactive surface plot demonstrate that the fluorescence intensities are the highest at the sites 
of dysplasia, a phenomenon that was observed in all three tracer-dose cohorts. (B) Three representative fluorescence microscopy images, demonstrating an observable 
difference in fluorescence intensities between the three dose cohorts: the 4.5 mg cohort shows a lower signal in the 800 nm channel, compared to the two higher dose cohorts. 
Fluorescence microscopy did not show a clear difference between the two highest dose cohorts (10 mg vs 25 mg). The left column represents the fluorescence of the tracer (800 
nm channel), the middle column shows Hoechst staining of the nuclei and third column displays an overlay of the previous two channels. (C) Representative microscopy images 
of one adenoma of the 25 mg dose cohort, showing a clear difference in NIR fluorescent signal between areas containing dysplasia and areas containing normal colon crypts; the 
areas can be distinguished based on the appearance of the crypts, since stacking of the nuclei is typical for dysplasia. 






Figure 6. VEGFA immunohistochemistry results. (A) Box plot (median, 10-90 percentile) and bar graph, both presenting VEGFA IHC results (H-score) of adenomatous 
colorectal polyps (LGD and normal crypts) and normal colorectal biopsies; a clear difference in H-score can be observed between the adenomatous crypts and the normal 
surrounding tissue and normal biopsies. (B) Representative images illustrating the clear difference in VEGFA staining intensities (brown) between dysplastic and normal crypts 
(areas within dashed yellow lines display normal crypts).  
 
To identify the optimal dose, adequate 
fluorescent signal quantification is essential since it 
validates the observed in vivo fluorescent signals. The 
background tissue optical properties, i.e., absorption 
and scattering, make quantitative measurements on in 
vivo NIR-FME images complicated. MDSFR/SFF 
spectroscopy can correct raw fluorescent signals for 
the influence of the local tissue optical properties and 
was previously validated in silico and in optical 
phantoms, and has been used in in vivo pre-clinical 
models [21-24]. The spectroscopy results showed that 
an adenoma-to-normal tracer concentration ratio of 
1.84 was sufficient to gain real-time visualization of 
adenomas (25 mg dose cohort). As this ratio is based 
on actual quantification using spectroscopy, it is not 
comparable to the usual adenoma-to-normal ratios 
given in other studies, only obtained by comparing 
contrast in reflectance images, as is signified by the 
clear contrast in our in vivo images. The applied 
bevacizumab dose of 25 mg is still far below the 
conventional therapeutic dose of 5-10 mg/kg and did 
not show any side-effects [11]. In addition, we 
subsequently calculated the actual bevacizumab- 
800CW concentration in the tissue with the 
assumption that the in silico measured fluorescence 
quantum yield and extinction coefficient of 
bevacizumab-800CW are representative for the in vivo 
conditions.  
Although our results are promising, our 
proof-of-principle study has some limitations. First, as 
the lesions were concurrently detected by white-light 
endoscopy and NIR-FME, this study cannot address 
the effect of NIR-FME on improving the adenoma 
detection rate. Secondly, FAP patients are not an ideal 
patient population for evaluating adenoma detection 
miss rates, since they are known to have multiple 
areas with aberrant crypt foci, and most patients have 
an ileorectal anastomosis. Nevertheless, we 
deliberately performed this proof-of-principle study 
in FAP patients to ensure sufficient adenoma numbers 
to identify the optimal tracer dose, despite the limited 
number of available patients. Twenty-five mg 
bevaciumab-800CW may well be universally used to 
detect the important SSA/Ps and high-risk Lynch 
lesions, since we previously showed 94% 
overexpression of VEGFA in sporadic adenomas 
(with similar etiology as adenomas of FAP patients), 
and a comparable 95% in SSA/Ps and 79-96% 
overexpression in LS patients [8].  
In conclusion, this study demonstrates that 
VEGFA-targeted NIR-FME is a promising optical 
molecular red-flag imaging approach for colorectal 





adenoma detection: our novel probe-based NIR-FME 
approach meets the current clinical standards since it 
provides real-time molecular guidance, and thus 
functional information, without interfering with the 
regular HD morphological information of white-light 
endoscopy. Following IV administration of 25 mg of 
bevacizumab-800CW, NIR-FME highlighted very 
small dysplastic adenomas with high in vivo 
fluorescent contrast at video-rate, which was 
confirmed by MDSFR/SFF spectroscopy. Future 
studies are required to determine the effect of 
NIR-FME using 25 mg of bevacizumab-800CW on 
improving the adenoma detection rate of flat and 
depressed adenomas compared to white-light 
endoscopy and the thereby the clinical benefit for 
patients at high risk of developing colorectal cancer, 
for example patients with Lynch syndrome.  
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